BofA downgraded Candel Therapeutics (CADL) to Neutral from Buy with a $7 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics appoints Carl June to Research Advisory Board
- Candel Therapeutics Extends Lease Agreement in Needham
- Candel Therapeutics Advances with Promising Cancer Therapies
- Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment
- Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Market Potential